Canada's Rubicon Organics misses Q3 revenue estimates

Rubicon Organics

13/11/2025 08:48

Overview

Rubicon Organics Q3 2025 revenue up 16% yr/yr, slightly missing analyst expectations

Company achieved Q3 2025 adjusted EBITDA of C$1.7 mln

Obtained Health Canada license for Cascadia Facility, operations to begin soon

Outlook

Company forecasts full-year growth in net revenue and Adjusted EBITDA for 2025

Rubicon expects Cascadia Facility revenue in first half of 2026

Company anticipates Cascadia Costs will impact 2025 financial results

Result Drivers

OPERATIONAL SCALE - Rubicon attributes revenue growth to benefits of operational scale and disciplined cost control

CASCADIA FACILITY - Health Canada license obtained for Cascadia Facility, expected to expand production capacity by over 40%

MARKET SHARE - Achieved notable market share in premium cannabis segments, including #1 topical SKU

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Miss*
C$15.60 mln
C$15.70 mln (2 Analysts)
Q3 Adjusted EBITDA
C$1.70 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Rubicon Organics Inc is C$1.15, about 55.7% above its November 12 closing price of C$0.51

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release: ID:nGNXyF8tJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)